StockDuty ← Dashboard Jul 07, 2026 09:41 PM ET
CatalystFDA/Bio

COMPASS PATHWAYS PLC (CMPS) DISCUSSES SIX-MONTH DATA FROM SECOND PHASE 3 TRIAL CONFIRMING RAPID AND DURABLE PROFILE IN DEPRESSION TRANSCRIPT - SEEKINGALPHA

Phase 3 data confirms rapid and durable depression treatment profile over six months.

Phase 3 data confirms rapid and durable depression treatment profile over six months.
Sources